36 unknown. 36 Phase 2, 7 Phase 3, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 36 | Unknown 36 |
| Phase 3 | 7 | Unknown 7 |
| Phase 1 | 5 | Unknown 5 |
Follow Thyroid Diseases: new trials by email Literature Review of Thyroid Diseases trials Research Report on Thyroid Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer 20 mg Famitinib & 1200 mg Adebrelimab - Thyroid Cancer | Phase 2 | Unknown | Ruijin Hospital | 67 | 2023-12-01 | 2023-11-28 |
| Effect of Vitamin C Supplementation in Patients With Primary Hypothyroidism Vitamin C, Oral Rehydration Salt Formulations - Hypothyroidism, Primary Hypothyroidism | Phase 2 | Unknown | Dr Adnan Agha | 40 | 2023-11-01 | 2024-01-11 |
| Graves' Disease Remission Study: MycoMeth Combo Mycophenolate Mofetil, Oral, 250 Mg, methimazole, oral, 10mg - Graves' Disease | Phase 2 / Phase 3 | Unknown | The First Affiliated Hospital of Xiamen University | 205 | 2023-10-16 | 2024-02-28 |
| Patient-Customized Bioprinting Technology for Practical Regeneration of the Respiratory Tract (Trachea) Three-dimensional patient-specific bioprinting trachea implantation - Thyroid Cancer | Phase 1 / Phase 2 | Unknown | Ja Seong Bae, MD, phD | 1 | 2023-07-17 | 2023-09-25 |
| A Study of DB-1202 Monotherapy in Advanced Solid Tumors DB-1202 - Advanced Solid Tumor | Phase 1 / Phase 2 | Unknown | DualityBio Inc. | 150 | 2023-06-28 | 2023-03-31 |
| Sirolimus for Graves' Orbitopathy (GO) Sirolimus - Graves Ophthalmopathy | Phase 2 | Unknown | University of Pisa | 54 | 2023-06-01 | 2023-03-15 |
| PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer Tislelizumab, Anlotinib, Radiotherapy - Thyroid Cancer | Phase 2 | Unknown | West China Hospital | 20 | 2022-12-30 | 2022-12-21 |
| A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study) Dabrafenib 75 MG, Trametinib 2 MG - Thyroid Cancer | Phase 2 | Unknown | Olivia Newton-John Cancer Research Institute | 80 | 2022-07-14 | 2023-10-31 |
| Bupivacaine Versus Lidocaine Infiltration for Postoperative Pain in Thyroid Surgery Bupivacaine 0.5% with 1:200 000 epinephrine, Lidocaine 2% with 1:100 000 epinephrine - Postoperative Pain, Thyroid Diseases | Phase 2 | Unknown | St. Joseph's Healthcare Hamilton | 210 | 2022-06-01 | 2023-11-28 |
| A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease HBM9161 680 mg qw by q2w from week 13, Placebo, HBM9161 680 mg qw by q2w from week 7 - Thyroid Ophthalmopathy | Phase 2 / Phase 3 | Unknown | Harbour BioMed (Guangzhou) Co. Ltd. | 36 | 2021-09-22 | 2022-02-23 |
| Anlotinib or Penpulimab in Combination With RAI for DTC Anlotinib hydrochloride, Sodium Iodide I 131, Penpulimab - Thyroid Cancer | Phase 2 | Unknown | Peking Union Medical College Hospital | 42 | 2021-09-15 | 2022-01-28 |
| Metastatic Thyroid Cancer Therapy Optimization With 124I PET Dosimetry Radioiodine optimized therapy - Metastatic Differentiated Thyroid Cancer | Phase 2 | Unknown | Carlo Chiesa | 50 | 2021-05-12 | 2022-03-29 |
| Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy dabrafenib and trametinib - Thyroid Cancer | Phase 2 | Unknown | National University Hospital, Singapore | 5 | 2020-12-30 | 2021-03-05 |
| Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer Camrelizumab and Apatinib, surgery, core needle biopsy - Thyroid Cancer | Phase 2 | Unknown | Fudan University | 31 | 2020-12-01 | 2020-11-03 |
| Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study Surufatinib, Toripalimab - Thyroid Cancer | Phase 2 | Unknown | Fudan University | 10 | 2020-10-01 | 2020-08-24 |
| Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer Anlotinib, surgery, core needle biopsy - Thyroid Cancer | Phase 2 | Unknown | Fudan University | 13 | 2019-06-01 | 2021-04-01 |
| Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers Apatinib - Thyroid, Metastasis | Phase 2 | Unknown | Nanjing First Hospital, Nanjing Medical University | 10 | 2019-04-10 | 2019-11-27 |
| A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib - Colorectal Cancer Not MSI-H or MMR-deficient, GIST | Phase 1 / Phase 2 | Unknown | Institut BergoniƩ | 747 | 2018-05-04 | 2023-03-03 |
| Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition Trametinib 2 MG [Mekinist], Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2) [Tafinlar] - Metastatic Thyroid Cancer | Phase 2 | Unknown | University Hospital, Essen | 70 | 2018-02-05 | 2023-06-22 |
| Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer Apatinib, Intensity modulated radiation therapy - Thyroid Cancer | Phase 2 | Unknown | Xiayun He, MD | 20 | 2017-07-01 | 2017-10-03 |
Showing 20 of 36. Sign in to see all of them.
Thyroid Neoplasms (21) · Graves Ophthalmopathy (5) · Graves Disease (4) · Adenocarcinoma, Follicular (3) · Stomach Neoplasms (3) · Thyroid Cancer, Papillary (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Colonic Neoplasms (2) · Head and Neck Neoplasms (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Thyroid Carcinoma, Anaplastic (2)
Endocrine System Diseases (35) · Endocrine Gland Neoplasms (22) · Neoplasms (22) · Neoplasms by Site (22) · Head and Neck Neoplasms (20) · Immune System Diseases (9) · Autoimmune Diseases (8) · Exophthalmos (8) · Goiter (8) · Orbital Diseases (8) · Eye Diseases (7) · Hyperthyroidism (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Genetic Diseases, Inborn (6)
apatinib (4) · dabrafenib (3) · trametinib (3) · Biopsy, Large-Core Needle (2) · Bupivacaine (2) · Iodine-131 (2) · Radiotherapy (2) · Surgical Procedures, Operative (2) · anlotinib (2) · Ascorbic Acid (1) · Botulinum Toxins, Type A (1) · Chlortetracycline (1) · Clinical Trials, Phase II as Topic (1) · Doxycycline (1) · Everolimus (1)
Fudan University (3) · National Cancer Center, Korea (2) · Sun Yat-sen University (2) · Carlo Chiesa (1) · Chinese Academy of Medical Sciences (1) · Dr Adnan Agha (1) · DualityBio Inc. (1) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · Harbour BioMed (Guangzhou) Co. Ltd. (1) · Hospices Civils de Lyon (1) · Institut BergoniĆ© (1) · Ja Seong Bae, MD, phD (1) · Leiden University Medical Center (1) · Nanjing First Hospital, Nanjing Medical University (1) · National University Hospital, Singapore (1)
China (13) · South Korea (4) · Italy (3) · France (2) · Germany (2) · United States (2) · Australia (1) · Canada (1) · Iran (1) · Netherlands (1) · Singapore (1) · Switzerland (1) · United Arab Emirates (1)
Dan Liang, MD (2) · Adnan Agha (1) · Alan B Scott, MD (1) · Andrew M Scott, MD, FRACP (1) · Babak Babsharif, MD (1) · Carlo Chiesa, PhD (1) · Electron Kebebew, MD (1) · Ellen Kapiteijn, MD, PhD (1) · Eun Kyung Lee, M.D.,Ph.D. (1) · Fangsen Xiao, MD (1) · Feng Wang, PhD MD (1) · Furio Pacini, MD (1) · Han Zhang, MD FRCSC (1) · Huifang Zhou (1)
PMID 18299459, PMID 20126486, PMID 22479375, PMID 26041482, PMID 26163763, PMID 26670972, PMID 27169792, PMID 27272078, PMID 27521067, PMID 27797318, PMID 29396246, PMID 30105951, PMID 30261427, PMID 30912336, PMID 32055040, PMID 32616746, PMID 32929476, PMID 34598995, PMID 34610756, PMID 34965951, PMID 34998048, PMID 35223896, PMID 35767182, PMID 35959915, PMID 36173609, PMID 36346684, PMID 40204996, PMID 40579407, PMID 41210509
2016 (2)